HomeCompareRHNMF vs PFE

RHNMF vs PFE: Dividend Comparison 2026

RHNMF yields 10526.32% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RHNMF wins by $91421458538285344.00M in total portfolio value
10 years
RHNMF
RHNMF
● Live price
10526.32%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$91421458538285344.00M
Annual income
$89,744,322,218,307,970,000,000.00
Full RHNMF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — RHNMF vs PFE

📍 RHNMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRHNMFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RHNMF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RHNMF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RHNMF
Annual income on $10K today (after 15% tax)
$894,736.84/yr
After 10yr DRIP, annual income (after tax)
$76,282,673,885,561,770,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, RHNMF beats the other by $76,282,673,885,561,770,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RHNMF + PFE for your $10,000?

RHNMF: 50%PFE: 50%
100% PFE50/50100% RHNMF
Portfolio after 10yr
$45710729269142672.00M
Annual income
$44,872,161,109,153,986,000,000.00/yr
Blended yield
98.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

RHNMF
No analyst data
Altman Z
-9.5
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RHNMF buys
0
PFE buys
0
No recent congressional trades found for RHNMF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRHNMFPFE
Forward yield10526.32%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$91421458538285344.00M$49.6K
Annual income after 10y$89,744,322,218,307,970,000,000.00$26,258.71
Total dividends collected$91309952364754128.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RHNMF vs PFE ($10,000, DRIP)

YearRHNMF PortfolioRHNMF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,063,332$1,052,631.58$9,153$693.39+$1.05MRHNMF
2$105,744,905$104,607,140.08$8,593$849.25+$105.74MRHNMF
3$9,835,430,757$9,722,283,708.79$8,336$1,066.78+$9835.42MRHNMF
4$855,644,041,989$845,120,131,078.84$8,437$1,384.80+$855644.03MRHNMF
5$69,627,827,846,009$68,712,288,721,080.95$9,013$1,875.40+$69627827.84MRHNMF
6$5,300,152,192,813,391$5,225,650,417,018,161.00$10,306$2,680.72+$5300152192.80MRHNMF
7$377,430,657,448,967,200$371,759,494,602,656,830.00$12,820$4,101.38+$377430657448.95MRHNMF
8$25,145,413,383,015,215,000$24,741,562,579,544,820,000.00$17,673$6,826.70+$25145413383015.20MRHNMF
9$1,567,417,121,474,185,500,000$1,540,511,529,154,359,300,000.00$27,543$12,591.86+$1567417121474185.50MRHNMF
10$91,421,458,538,285,340,000,000$89,744,322,218,307,970,000,000.00$49,560$26,258.71+$91421458538285344.00MRHNMF

RHNMF vs PFE: Complete Analysis 2026

RHNMFStock

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. The company's products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. It also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is headquartered in Cremorne, Australia.

Full RHNMF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this RHNMF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RHNMF vs SCHDRHNMF vs JEPIRHNMF vs ORHNMF vs KORHNMF vs MAINRHNMF vs JNJRHNMF vs MRKRHNMF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.